Skip to main content
. 2015 Aug 21;6(30):29388–29395. doi: 10.18632/oncotarget.5001

Figure 3. A false negative case involving a T2N1 breast primary lesion (HER2-positive) and right axillary lymph node metastasis before and after neoadjuvant chemotherapy (NAC) plus trastuzumab.

Figure 3

Transverse slices of CT and PET images show that the size of the right axillary lymph node (ALN) metastasis is 2.3 × 1.3 cm A. with high FDG uptake and a baseline SUVpeak of 5.16 B. After NAC plus trastuzumab treatment, the right ALN shrank C.; FDG uptake decreased and the SUVpeak was 2.72 D. The ΔSUVpeak is − 47% (from 5.16 to 2.72), less than the threshold of − 80%, but the result of ALN dissection was pathological complete response. ΔSUVpeak refers to the difference in standard uptake values between baseline and after two NAC cycles.